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Introduction
Interest in zinc lozenges for treating the common cold arose when the cold symptoms of a 3-year-old girl with leukemia disappeared soon after she dissolved a therapeutic zinc tablet in her mouth instead of swallowing it as instructed [1] . The benefit seemed to be obtained from slowly dissolving the tablet in her mouth, which suggested that zinc might have local effects in the pharyngeal region. This observation led the girl's father to conduct the first randomized placebocontrolled trial on the effects of zinc lozenges on common cold patients. In that study, zinc gluconate lozenges shortened the duration of colds significantly [1] .
Since then, a series of trials on zinc lozenges have been carried out but the results were variable [2] [3] [4] [5] . The daily dosage of elemental zinc in the trials had a 7-fold variation, which explains much of the inconsistency in the study findings [2] . The composition of the lozenges also differed; some of them contained substances that bind zinc tightly, preventing the release of free zinc ions. The composition differences also explain divergent results [3] [4] [5] [6] .
A previous meta-analysis indicated that 5 low-dose trials of zinc lozenges (<75 mg/d zinc) uniformly produced no effect on the duration of colds. However, 3 high-dose (>75 mg/d) zinc acetate trials produced a 42% reduction in the duration of colds on average, and 5 high-dose zinc gluconate trials found a 20% reduction in cold duration on average [2] . Since acetate binds zinc ions less strongly than gluconate, zinc acetate has been proposed as the best salt for lozenges [4, 5] . Although dissolving lozenges in the oro-pharyngeal region leads to the highest zinc levels in that anatomical region, a recent meta-analysis found no evidence that zinc acetate lozenges have less effect on nasal symptoms compared with cold symptoms that originate in lower anatomical regions [7] . Other systematic reviews on zinc and the common cold have been published [8] [9] [10] , but some of them had methodological problems [11] [12] [13] , and a Cochrane review was recently withdrawn [14] .
Petrus et al. [15] reported that common cold patients who had positive skin testing for allergies were more responsive to the zinc acetate lozenges than those who were negative for allergies, but that association has not been analyzed in later studies. The effect of zinc lozenges might also be modified by smoking which influences the respiratory system, and by the severity of the common cold which reflects different levels of pathologic changes caused by the respiratory viruses. The goal of the present individual patient data (IPD) meta-analysis was to determine whether the efficacy of high-dose zinc acetate lozenges varies by the allergy status, smoking, baseline common cold severity or by demographic characteristics.
Methods

Selection of the trials
This meta-analysis was restricted to placebo-controlled trials on zinc acetate lozenges for patients with naturally acquired common cold infections, in which the elemental zinc dosage was >75 mg/d. We restricted the selection to high-dose trials, since previous analyses demonstrated the lack of effect of low doses of zinc, < 75 mg/day [2, 4, 5, 10] . Previous searches of the literature [2, 5, [8] [9] [10] ] identified 3 trials that met our selection criteria [15] [16] [17] . These three trials are shown in Table 1 and further characteristics are shown in Supplement file 1. No additional zinc acetate lozenge trials were found by searching PubMed and Scopus using the free search terms "zinc" and "lozenge*" (June 16, 2016) . The three datasets for this IPD meta-analysis were made available with the cooperation and collaboration of the authors of the three trials and the lead author. We did not use a protocol for this meta-analysis.
Outcome
The outcome in this meta-analysis was the duration of colds. Petrus et al. (1998) [15] reported both the mean duration of common cold symptoms and the duration of the longest cold symptom. We used the latter as the outcome for this analysis, since it is consistent with the outcome definition in the two studies by Prasad et al. [16, 17] .
Statistical methods
In checking of the IPD for the three studies, we confirmed that the effects of zinc lozenges in the IPD data were consistent with the published effects [15] [16] [17] .
Pooling of the IPD was done by the one-stage and two-stage approaches. One-stage metaanalysis indicates that the pooled effect estimates are calculated directly from the IPD. Two-stage meta-analysis indicates that the effect estimates of the individual studies are first calculated from the IPD; thereafter, those study level estimates are pooled by standard meta-analysis methods. In some cases, the one-stage meta-analysis has greater statistical power and sometimes the two approaches lead to different conclusions [18] .
We used the lmer procedure of the lme4 statistical package of R [19] for the one-stage metaanalysis. In the mixed models constructed with lmer, we used the study as the random variable for the zinc effect and also as an independent explanatory variable. The interaction between the zinc lozenge effect and each subgroup variable was calculated by first adding the zinc effect and the subgroup variable to the basic model, and thereafter adding their interaction term; the interaction between zinc and the subgroup variable was added as a random variable. The p-value for the interaction was calculated by using the likelihood ratio test.
In the two-stage pooling, we first used the lm procedure [19] to calculate the mean effects and the zinc-subgroup interactions separately in the three trials. Thereafter we pooled those effects by the metagen procedure of the meta package using the inverse-variance and random-effects options [19] . The p-value for the interaction was calculated from the z-value of the pooled interaction effect. We used the χ 2 test and the I 2 statistic to assess statistical heterogeneity among the three trials in the two-stage approach. A value of I 2 greater than about 70% indicates a high level of heterogeneity [20] .
We used the difference in the duration of colds in days as the main measure of the zinc effect. However, since the distributions of viruses differ over time and the operational outcome definitions vary between trials, variation between studies is to be expected. Since relative effect adjusts for variation in the common cold duration in the placebo groups, we also calculated the overall effect of zinc in the percentage scale so that the duration of each placebo group was normalized to 100%. Thereby the difference between the zinc group and the placebo group directly gives the effect of zinc lozenges in percentages.
Our calculations are described in detail in Supplement file 2. Two-tailed p-values are used. Table 1 shows the distributions of the baseline variables of the three trials analyzed in this IPD meta-analysis. The trials had 199 common cold patients with the majority being females. Eighty percent of the common cold patients fell into the age range between 20 and 50 years. The majority was white, 23% were African Americans and 10% were of other ethnic origin. In the Petrus et al. study, all common cold patients were skin tested with 20 different allergy extracts including grasses, trees, and cat and dog dander, and 46% of the patients tested positive for allergies [15] , see details in Supplement file 1. In their two trials, Prasad et al. asked about allergies with a questionnaire and 12% [16] and 20% [17] reported having allergies. Petrus et al. did not record information about smoking, whereas in the two studies by Prasad et al., a quarter of participants were smokers. All three studies were randomized, double-blind, placebo-controlled trials, and there were few dropouts. Further details of the methodology of the three trials are described in Supplement file 1.
Results
Petrus et al. instructed patients to dissolve in their mouth 1 lozenge every 1½ hour while awake on the first day, and then 1 lozenge every 2 hours on the following days; lozenges dissolved in about 15 minutes [15] . Prasad et al. instructed patients to dissolve 1 lozenge in their mouth every 2 to 3 hours while awake; their lozenges dissolved in about half an hour [5, 16, 17] . Elemental zinc dose varied between 80 and 92 mg/day in the three studies (Supplement file 1). Table 2 shows the estimated effect of zinc acetate lozenges over all participants. The one-stage meta-analysis gives an estimate of a 2.73 day reduction in common cold duration and the two-stage meta-analysis gives an estimate of 2.94 days. These estimates are to be compared with the 7 day average duration of colds in the three trials ( Table 2 ). The small difference between the two pooled estimates is explained by the substantially greater zinc effect and smaller SDs in the two small studies by Prasad et al Table 2 . The two-stage method gives a greater effect estimate for zinc lozenges since the total weight of the two studies by Prasad is 75%, although the number of participants is essentially equal with the Petrus et al. study [15] , see forest plot in Supplement file 2.
The effectiveness of zinc acetate lozenges on the duration of colds on the relative scale is also shown in Table 2 . One-stage IPD meta-analysis gave an estimate of 36% average reduction in common cold duration and the two-stage pooling gave an estimate of 40% average reduction in the duration of colds. Table 3 shows the one-stage subgroup analyses of the zinc lozenge effects. The table shows the difference in the zinc lozenge effect between the complementary subgroups. The effect of zinc acetate lozenges was not modified by allergy, smoking, baseline severity of the cold, age, sex, or ethnic group. Age was analyzed as a continuous variable and no interaction with zinc effect was seen for that variable either. The two-stage approach gave similar results, see Supplement file 2. In the two-stage subgroup analysis, there was no heterogeneity in the interaction between the zinc effect and subgroups between the three trials.
Discussion
The effect of zinc acetate lozenges on the common cold was not modified by allergy, smoking, baseline severity of the common cold, age, sex, or ethnic group (Table 3) . Our IPD meta-analysis does not support the earlier indication that zinc lozenges might be more effective for participants who have allergies [15] .
Since no subgroup differences were found in the effect of zinc acetate lozenges, the overall estimates calculated in Table 2 are the most useful estimates for common cold participants comparable to the patients included in these three trials. Thus, given an average common cold duration of approximately one week (Table 2) , zinc acetate lozenges may shorten common cold duration by an average of 3 days over various population groups.
A previous meta-analysis of the same three trials calculated that zinc acetate lozenges shortened the duration of colds on average by 42% [2] . That calculation was based on fixed-effect pooling of the reported study-level estimates. The current one-stage and two-stage IPD meta-analyses give similar overall estimates, though the current study calculated random-effects models.
Our meta-analysis was restricted to three studies with zinc acetate lozenges. Since there is evidence that acetate binds zinc ions less strongly than gluconate, zinc acetate has been proposed as a more suitable salt for lozenges than zinc gluconate [4, 5] . Nevertheless, three studies with high doses of zinc as zinc gluconate also reported a statistically significant 21% to 48% reduction in the duration of colds [1, 21, 22] ; see meta-analysis in [2] . The data of those old zinc gluconate studies were no longer available and we restricted our subgroup analysis to the three zinc acetate trials for which we had the IPD available.
Farr and Gwaltney [23] speculated that the apparent benefit of zinc gluconate lozenges reported by Eby (1984) [1] might have been explained by the bad taste of the lozenges. However, none of the three zinc acetate lozenge trials included in our meta-analysis showed that bad taste was a problem. There was no substantial difference between the zinc and placebo groups in the occurrence of adverse effects and only a few dropouts occurred [15] [16] [17] . In the most recent trial [17] , a few patients identified the type of lozenge that they were administered, but when the analysis was restricted to those who remained blinded at the end of the trial, the efficacy of zinc lozenges was comparable to the efficacy for all participants.
Zinc doses of 100 to 150 mg/day have been administered to certain patient groups for months with few adverse effects [2, [24] [25] [26] [27] . Thus, it is unlikely that a zinc dose of some 80 mg/day for one to two weeks, starting soon after the first common cold symptoms, might cause long-term adverse effects. If a patient considers that the taste of the zinc lozenge is bad, he or she can discontinue using the lozenges, whereas other common cold patients may continue its use. Although the evidence is strong that properly formulated zinc lozenges can shorten the duration of colds, it appears that the majority of zinc lozenges on the market have either doses of zinc which are too low or contain substances that bind zinc, such as citric acid [5] . Therefore, the findings of this analysis should not be directly generalized to the wide variety of zinc lozenge formulations on the market.
In conclusion, our IPD meta-analysis found that the effect of zinc acetate lozenges on the duration of the common cold is not modified by allergy, smoking, baseline common cold severity, age, sex, or ethnic group. The calculated 3 day and 36% estimates for the reduction of common cold duration are substantial effects and worth utilizing by common cold patients. The optimal composition of zinc lozenges and the best frequency of their administration should be further investigated. Nevertheless, given the current evidence of efficacy and the low rate of adverse effects, common cold patients may be encouraged to try zinc acetate lozenges for treating their colds.
Supplement file 1: Description of the three studies included. See at the end of this manuscript. Supplement file 2: Description of the statistical calculations. See at the end of this manuscript.
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Zinc acetate lozenges for treating the common cold: an individual patient data meta-analysis
Randomization "The bottles of the zinc lozenges and placebo were sent by the manufacturer and each bottle was identical except a sequential number. At registration, after qualifying for the study each patient was given a bottle of 180 lozenges. At the conclusion of the study, when the diaries were assembled, the code for the bottles was sent by the manufacturer, and the patients were placed in the zinc or placebo category. Then the results were tabulated and the statistical analysis was undertaken" (Edward Petrus 24 March 2016).
Allocation concealment Patients and personnel did not know to which group the patients were allocated.
Blinding of patients and personnel Reported as double-blind, which implies that patients and personnel were blinded.
Blinding of outcome assessment
Blinded "subjects were also informed that they were required to rate and record their symptoms in a diary " (p. 598). "Subjects recorded their symptoms every day until their symptoms ceased (p. 598).
Losses to follow-up 1 patient was lost to follow-up.
Patients
Included in the analysis: 52 Zn and 49 placebo patients 47 M 54 F, mean age 26 yr (range 18 to 54 yr)
Patients were recruited from the campus of the University of Texas through posted announcements
Exclusions: serious illnesses, organ transplants, disability "This study was conducted during July and August 1997, when pollen was at its lowest level" (p. 598).
Common cold definition Presence of 2 or more of the following 11 symptoms: nasal drainage, nasal congestion, cough, fever, myalgia, headache, sore throat, scratchy throat, hoarseness, sneezing, malaise (p. 598).
Delay between cold onset and treatment initiation "97 of the 101 subjects started using zinc lozenges on the first day of enrollment in the study (4 started on day 2 of enrollment), but the dataset doesn't contain any information on the length of time between onset of symptoms and start of zinc therapy" (Kenneth Lawson, email 11 Dec 2014).
Outcome definition Two outcomes were reported: 1) mean duration of all observed cold symptoms of the individual 2) duration of the longest-lasting common cold symptom.
Measurement of severity of the baseline cold "Subjects were also informed that they were required to rate and record their symptoms in a diary at the same time each day. Symptoms [see the 11 symptoms above] were graded as follows: 0 = absent; 1 = mild (symptom is present but not particularly a discomfort); 2 = moderate (symptom is clearly evident and a discomfort); or 3 = severe (symptom is a serious problem and clearly evident and a discomfort)" (p. 598).
Thus, the maximum of the scale was 33 points. The recorded level of severity at the baseline varied from 2 to 23 points, with the median at 7 points.
Intervention
Zn acetate: one lozenge contained 9 mg Zn (p. 597). Placebo lozenges contained sucrose octaacetate.
Patients were instructed to use 1 lozenge every 1½ hour while awake during day 0, then 1 lozenge every 2 hour while awake on following days. Lozenges "The lozenges with zinc contained 9 mg of zinc in a 2.7 g dextrose base" (p. 597). "To achieve masking, sucrose octaacetate (0.169 mg) was used in the placebo, and both the placebo and zinc lozenges were peppermint flavored. A review of subjects' diary entries revealed that 4 subjects noted a chalky taste, 4 experienced a metallic aftertaste, and 3 complained of an upset stomach; none of the subjects noted a bitter taste. Most subjects liked the peppermint flavor. " (p. 599). "The lozenges ... dissolved in the mouth in about 15 minutes" (p. 602).
"Lozenges dissolved in about 15 min " (p. 31 on [8] ).
"The Petrus and Prasad compressed lozenges were designed by the present author and were identical in composition. In addition to ZA, they contained directly compressible (agglomerated) dextrose as the tablet base, glycerol mono-stearate (2.5% tablet weight) as tablet lubricant, stevia for added sweetness and peppermint oil for flavor, with the composition compressed to near maximal hardness for slowest dissolution. Those ingredients were chosen specifically because they do not react with iZn" (p. 31 in [8] ).
"Lozenges were small zinc acetate lozenges consisting of a dextrose tablet base, 2.5% glycerol monostearate lubricant, stevia and peppermint oil on silica gel compressed with a force sufficient to allow them to dissolve in 15 min in the human mouth" (p. 485 in [9] ).
Mean and SD of the common cold duration
Calculated from the IPD data set (the same as reported in 1998):
Zn: Mean duration of the longest-lasting symptom: 5.288 days (SD 2.569)
Placebo: Mean duration of the longest-lasting symptom: 7.061 days (SD 3.907).
Allergy testing "Because common colds and nasal allergies cause many of the same symptoms, skin tests were performed on each subject to determine whether allergies were present. All subjects were skin tested with 20 different allergy extracts, …The extracts included ragweed mix, burweed marsh elder, cedar elm, Bermuda grass, Johnson grass, perennial rye grass, mountain cedar (juniper), Virginia live oak, pecan, American elm, Alternaria alternata, Hormodenorum cladospo rioides, Helminthosporium sativum, cockroach mix (American and German), cat dander, dog dander, dust mite mix, Western ragweed, a negative control (diluent), and a positive control (histamine). After a 15-to 30-minute waiting period, the results of the skin test were measured and recorded. Itching, swelling, or redness at the site of allergy extract application indicated a positive reaction to the allergen. Forty-six subjects (46%) tested positive for allergies, and 55 (54%) were negative" (pp. 597-598).
Adverse effects "Only 1 subject was lost to follow-up, and none of the remaining 101 subjects discontinued because of side effects from the lozenges. .. A review of subjects' diary entries revealed that 4 subjects noted a chalky taste, 4 experienced a metallic aftertaste, and 3 complained of an upset stomach; none of the subjects noted a bitter taste. Most subjects liked the peppermint flavor" (p. 599). 
Randomization "A research consultant prepared the randomization code and the packages of medication. The packages were identical in appearance except for the randomization numbers. A research assistant who was blinded to treatment assignments distributed the study medication" (p. 246).
Blinding of patients and personnel "A research assistant who was blinded to treatment assignments distributed the study medication" (p. 246).
Blinding of outcome assessment
Blinded "participants were asked to complete a daily log documenting the severity of symptoms" (p. 246).
Losses to follow-up "Two persons in the placebo group dropped out on day 2. One of the two persons had a sore mouth, and the other developed an ear infection for which care was transferred to a physician outside of Detroit Medical Center" (Legend to Patients were students, staff, and employees at Wayne State University, Michigan, who were ≥18 yr. In general, subjects were recruited during fall and winter months. Exclusions: Pregnancy, a known immunodeficiency disorder, chronic illnesses, and previous use of zinc lozenges. Subjects with history of allergies were not excluded.
Common cold definition Presence of 2 or more of the following 10 symptoms: cough, headache, hoarseness, muscle ache, nasal discharge, nasal congestion, scratchy throat, sore throat, sneezing, and fever (p. 246).
Delay between cold onset and treatment initiation Inclusion required that the cold had lasted for 24 hours or less.
Outcome definition "Resolution of cold symptoms was defined as the resolution of all symptoms (a total symptom score of 0) or the resolution of all but one mild symptom (a total symptom score of 1)" (p. 246).
Measurement of severity of the baseline cold "Participants were asked to complete a daily log documenting the severity of symptoms [see the 10 symptoms above] and the medications taken throughout the duration of the cold. Every day, the participants graded each symptom as 0 for none, 1 for mild, 2 for moderate, and 3 for severe. Total symptom scores were calculated by summing the scores " (p. 246).
Thus, the maximum of the scale was 30 points. The recorded level of severity at the baseline varied from 2 to 26 points, with the median at 11 points. "The Petrus and Prasad compressed lozenges were designed by the present author and were identical in composition. In addition to ZA, they contained directly compressible (agglomerated) dextrose as the tablet base, glycerol mono-sterate (2.5% tablet weight) as tablet lubricant, stevia for added sweetness and peppermint oil for flavor, with the composition compressed to near maximal hardness for slowest dissolution. Those ingredients were chosen specifically because they do not react with iZn [ionic zinc] . The slower dissolution of the 4-g size lozenges was an advantage over the smaller lozenges in terms of efficacy" (p. 31 on [8] ).
"Compressed with a force sufficient to allow them to dissolve in 30 min in the mouth" (p. 485 in [9] ).
Mean and SD of the common cold duration
Calculated from the IPD data set (the same as reported in 2000):
Zn group: mean cold duration: 4.480 days (SD 1.636)
Placebo group: mean cold duration: 8.086 days (SD 1.807)
Maintenance of blinding "Comparability in taste between zinc and placebo was tested in healthy volunteers. Ten participants were given a zinc lozenge and 10 received a placebo lozenge. One week later, the participants who received zinc were given placebo and those who received placebo were given zinc. At each visit, the participants filled out a questionnaire in which they were asked to guess whether they received a zinc or placebo lozenge. They had seven choices: certainly placebo, certainly zinc, do not know, possibly placebo, possibly zinc, probably placebo, and probably zinc. Volunteers who selected "certainly," "probably," or "possibly" and were correct about the type of lozenge they received were considered correct. We therefore categorized participants as "correct," "incorrect," or "do not know."
We assessed the adequacy of blinding among study participants by administering the questionnaire used to assess comparability of taste in healthy volunteers. Participants filled out the questionnaire at the beginning and at the end of the trial" (p. 247).
"Of 20 participants who received zinc, 5% [n=1]correctly guessed that they were receiving active therapy. Of 20 participants who received placebo, 10% [n=2] correctly guessed that they were receiving placebo. Therefore, participants did not correctly guess which type of lozenge they were receiving much better than by chance. In addition, at the beginning of the trial, 48% of zinc recipients and 26% of placebo recipients correctly identified the lozenges (P > 0.2). At the end of the study, 56% of zinc recipients and 26% of placebo recipients correctly identified the lozenges (P = 0.09). None of these percentages exceeded 50%, indicating that blinding was adequate at the outset and was maintained throughout the study" (p. 247-248).
Adverse effects "Except for mouth dryness and constipation, no statistically significant side effects occurred in zinc recipients compared with placebo recipients" (p. 250).
p. Common cold definition Presence of 2 or more of the following 10 symptoms: cough, headache, hoarseness, muscle ache, nasal drainage, nasal congestion, scratchy throat, sore throat, sneezing, and fever (p. 796).
Delay between cold onset and treatment initiation
Inclusion required that the cold had lasted for 24 hours or less.
Outcome definition "Resolution of cold symptoms was defined as the resolution of all symptoms (a total symptom score of 0) or the resolution of all but 1 mild symptom (a total symptom score of 1)" (p. 797).
Measurement of severity of the baseline cold "Participants were asked to complete a daily log documenting the severity of symptoms [see the 10 symptoms above] ... the subjects graded each symptom as 0 for none, 1 for mild, 2 for moderate, or 3 for severe. Total symptom scores were calculated by summing the scores of the 10 symptoms for each day" (p.
796-797).
Thus, the maximum of the scale was 30 points. The recorded level of severity at the baseline varied from 2 to 20 points, with the median at 8 points.
Intervention
Zn acetate: one lozenge contained 13.3 mg Zn (p. 796). Placebo lozenges contained sucrose octaacetate.
patients were asked to dissolve 1 lozenge in their mouth every 2 to 3 hr while awake.
The reported mean number of lozenges used per day in the Zn group was 6.9 (p. 799). Lozenges "The lozenges were cherry oil-flavored Fast Dry zinc acetate lozenges, manufactured by F & F Foods (Chicago, IL). The active lozenges contained 13.3 mg of zinc as zinc acetate in a hard candy that contained 3.8 g of sucrose and corn syrup and that was prepared using the open-pot batch method, with the active ingredient added last. 100% of the zinc was available at physiologic pH 7.4 in positively charged, ionic form. The placebo lozenges were of identical composition, except that they contained 0.25 mg of sucrose octaacetate rather than the active ingredient, zinc. There were no fats, metal chelators, or other zinc ion-binding agents in either the active or placebo lozenges. The placebo and zinc lozenges were identical in weight, appearance, flavor, and texture and were supplied by George Eby" (p. 796).
Calculation of the daily
Mean and SD of the common cold duration
Calculated from the IPD data set (the same as reported in 2008):
Zn group: mean cold duration: 4.00 days (SD 1.04)
Placebo group: mean cold duration: 7.12 days (SD 1.26)
Maintenance of blinding "Comparability in taste between zinc and placebo was tested in the participants at the beginning and the end of the trial. The participants filled out a questionnaire in which they were asked to guess whether they had received zinc or placebo lozenges. They had 5 choices: certainly placebo, certainly zinc, do not know, probably placebo, and probably zinc. Subjects who selected certainly or probably and were correct about the type of lozenges they received were considered to be correct. We therefore categorized participants as correct, incorrect, or do not know" (p. 797).
"In the zinc group at the beginning of the study, only 1 subject identified the lozenges as certainly zinc, and 2 subjects identified them as probably zinc. Thus, 3 (12%) of 25 subjects in this group were correct. At the end of the study, 2 (8%) were correct; 1 subject identified the lozenges as certainly zinc, and another subject identified them as probably zinc. In the placebo group at the beginning of the study, 1 subject said that the lozenges were certainly placebo, and another subject identified them as probably placebo. Thus, 2 subjects (8%) in this group were correct. At the end of the study, none of the subjects identified the placebo lozenge correctly" (p. 799).
Adverse effects "Adverse effects of the zinc and placebo lozenges are compared in table 3. The zinc and placebo groups did not differ significantly in the incidences of any of the adverse effects, including diarrhea, constipation, sweet taste, sour taste, bitter taste, aftertaste, dry mouth, mouth irritation, or bad taste. None of the subjects complained of either abdominal pain or vomiting" ( p. 799).
p. This is additional material to a manuscript by Hemilä et al. (2016) Statistical analyses of the studies are described in this file. Subgroup analysis of allergy for Table 3 is shown as an example of the mixed model calculations for the subgroup analyses. Table S1 shows the transformation of duration to the 100% scale Table S2 shows two-stage analysis of subgroup differences in zinc lozenge effects. The data set used in the study is printed at the end of this file.
This file contains:
Page 2  Table S1 : Normalization of common cold duration to Placebo group = 100% 3 Above table shows the transformation of the mean duration in the three studies to the percentage scale.
In Table 2 of the paper, the calculation of zinc acetate lozenge effect is done using the absolute scale of days (left-hand side of the table) and the relative scale (% effect on duration; right-hand side of the above table).
On the absolute scale, the Petrus (1998) study found an 1.77 day reduction in common cold duration (= 5.29 -7.06 days).
On the percentage scale, the Petrus (1998) study found an 25.1% reduction in common cold duration (= 74.9% -100% = 5.29/7.06 -1).
The relative scale has the benefit of adjusting for baseline variations between the placebo groups. Nevertheless, the absolute duration of the colds was used in the IPD subgroup analyses. Above median 97 +0.3 -1.2, + 1.7 0.7 * The minus sign in the estimate for the difference indicates that on average zinc lozenges have a greater effect in the second subgroup compared with the zinc lozenge effect in the reference group, or in older participants; however, the P-values indicate that all differences are due to chance variation. The modifying effect of age on the zinc lozenge effect is calculated for a 10 year interval. ** Ethnic groups other than white or African Americans were excluded from this comparison. 
Zinc effect and sex
No interaction between zinc effect and allergy ( P = 0.6) and no evidence of heterogeneity between studies (P = 0.6) 
Zinc effect and smoking
No interaction between zinc effect and smoking ( P = 0.7) and no evidence of heterogeneity between studies (P = 0.7) 
